Figure 2.

Rosiglitazone-induced multilocularization is reversible. The indicated adipose tissues were harvested from C57BL/6J mice that had been treated with nothing (Control), rosiglitazone (~15 mg/kg/day) for 3 weeks, or that had discontinued the rosiglitazone treatment for 1 week (Discon 1 week) or 2 weeks (Discon 2 week) after the rosiglitazone treatment for 3 weeks. (A) Tissues were whole-mounted, co-immunostained for perilipin and collagen IV, and merged. Note that rosiglitazone-induced multilocular adipocytes have reversibly recovered to unilocular adipocytes upon discontinuation of treatment. Scale bars, 20 µm. (B) Multilocular adipocytes were counted in 10 regions (~100 adipocytes/region) per adipose tissue in each mouse of Control (n = 3), rosiglitazone (n = 4), Discon 1 week (n = 4) or Discon 2 weeks (n = 4), and presented as a percentage of the total adipocytes counted. Bars represent the mean ± SD. ^*P < 0.01 versus control. ^#P < 0.05 versus rosiglitazone, 3 week.